in those patients who have a low probability of cardiac

dysfunction.
6,7
B-natriuretic peptide (BNP) is a cardiac neurohor-
mone secreted from the cardiac ventricles as a response
to ventricular volume expansion and pressure
overload.
8-10
BNP levels are elevated in patients with
symptomatic LV dysfunction and correlate with New
York Heart Association (NYHA) class as well as with
prognosis.
10-19
However, the utility of plasma BNP as a
screening test has been limited by the same standard
assay issues common to other hormones or cytokines
also elevated in heart failure.
20-22
By use of a rapid immunoassay for BNP, we sought to
determine whether BNP levels could serve as a screen
to patients referred for echocardiography at the San
Diego Veterans Health Care System.
Although patients with left ventricular (LV) dysfunc-
tion have improved survival on medications such as
angiotensin-converting enzyme inhibitors and -block-
ers,
1,2
this may be a difficult diagnosis to make by con-
ventional criteria.
3,4
No blood test can rapidly determine whether a patient
has LV dysfunction,
5
and echocardiography may not
always be cost-effective as a screening device, especially
From the Division of Cardiology and the Department of Medicine, Veterans Affairs
Medical Center and University of California, San Diego.
Submitted August 16, 2000; accepted November 29, 2000.
Reprint requests: Alan Maisel, MD, VAMC Cardiology 111-A, 3350 La Jolla Vil-
lage Dr, San Diego, CA 92161.
E-mail: amaisel@ucsd.edu
4/1/113215
doi:10.1067/mhj.2001.113215
Utility of B-natriuretic peptide as a rapid, point-of-
care test for screening patients undergoing
echocardiography to determine left ventricular
dysfunction
Alan S. Maisel, MD, FACC, Jen Koon, BSN, Padma Krishnaswamy, MD, Radmila Kazenegra, MD, Paul Clopton,
BSN, Nancy Gardetto, NC, Robin Morrisey, NC, Alex Garcia, BS, Albert Chiu, BS, and Anthony De Maria, MD,
FACC San Diego, Calif
Background Although echocardiography is an important tool for making the diagnosis of left ventricular (LV) dysfunc-
tion, the cost of this procedure limits its use as a routine screening tool for this purpose. Brain natriuretic peptide (BNP) accu-
rately reflects ventricular pressure, and preliminary studies have found it to be highly sensitive and highly specific in diagnos-
ing congestive heart failure in the emergency department. We hypothesized that BNP might therefore be useful as a
screening tool before echocardiography in patients with suspected LV dysfunction.
Methods Subjects included patients referred for echocardiography to evaluate the presence or absence of LV dysfunc-
tion. Patients with known LV dysfunction were excluded from analysis. BNP was measured by a point-of-care immunoassay
(Biosite Diagnostics, San Diego, Calif). The results of BNP levels were blinded from cardiologists making the assessment of
LV function. Patients were divided into those with normal ventricular function, abnormal systolic ventricular function, abnor-
mal diastolic function, and evidence of both systolic and diastolic dysfunction.
Results Two hundred patients in whom LV function was unknown were studied. In the 105 patients (53%) whose ven-
tricular function was subsequently determined to be normal by echocardiography, BNP levels averaged 37 6 pg/mL.
This was significantly less than in those patients with either ultimate diastolic dysfunction (BNP 391 89 pg/mL (P < .001)
or systolic dysfunction (BNP 572 115 pg/mL (P < .001). A receiver-operator characteristic curve showing the sensitivity
and specificity of BNP against the echocardiography diagnosis revealed the area under the curve (accuracy) was 0.95.
At a BNP level of 75 pg/mL was 98% specific for detecting the presence or absence of LV dysfunction by echocardiogra-
phy.
Conclusions A simple, rapid test for BNP, which can be performed at the bedside or in the clinic, can reliably predict
the presence or absence of LV dysfunction on echocardiogram. The data indicate that BNP may be an excellent screening
tool for LV dysfunction and may, in fact, preclude the need for echocardiography in many patients. (Am Heart J 2001;
141:367-74.)
Methods
Study population
The study was approved by the University of California
Institutional Review Board and conducted at the San Diego
Veterans Health care System between June and October
1999. Two hundred consecutive patients referred for echocar-
diography to evaluate LV function and consented to be stud-
ied were included from a total of 262 patients referred for LV
function during this time period. The 62 patients with known
LV dysfunction were excluded from analysis. Patients referred
for echocardiography to assess valve disease, the presence of
a vegetation, or to rule out a cardiac cause of stroke were not
included in this database. Both outpatients and inpatients
were included in this study, and approximately 24% of the
sampling population consisted of inpatients.
Echocardiography
Two-dimensional, M-Mode, spectral, and color flow Doppler
echocardiograms were obtained with commercially available
instruments operating at 2.0 to 3.5 mHz. Two-dimensional
imaging examinations were performed in the standard fashion
in parasternal long- and short-axis views and apical 4- and 2-
chamber views.
23
Pulsed Doppler spectral recordings were
obtained from a 4 4mm sample volume placed at the tips
of the mitral leaflets and in the pulmonary vein and that was
adjusted to yield the maximal amplitude velocity signals. All
data were copied to 0.5-inch VHS videotape for subsequent
playback, analysis, and measurement.
Two-dimensional echocardiograms were subjected to care-
ful visual analysis to detect regional contractile abnormalities.
LV systolic and diastolic volumes and ejection fractions were
derived from biplane apical (2- and 4-chamber) views with use
of a modified Simpsons rule algorithm.
24
The transmitral
pulsed Doppler velocity recordings from three consecutive
cardiac cycles were used to derive measurements as follows: E
and A velocities as the peak values reached in early diastole
and after atrial contraction, respectively, and deceleration
time as the interval from the E wave to the decline of the
velocity to baseline. In addition, pulmonary venous systolic
and diastolic flow velocities were obtained as the maximal val-
ues reached during the respective phase of the cardiac cycle,
and the pulmonary venous A reversal as the maximal veloc-
ity of retrograde flow into the vein after the P wave of the
electrocardiogram (ECG). Finally, the LV isovolumetric relax-
ation time (IVRT) was obtained from the apical 5-chamber
view with a continuous wave cursor or, if possible, a pulsed
Doppler sample volume positioned to straddle the LV outflow
tract and mitral orifice to obtain signals from aortic valve clo-
sure or the termination of ejection and mitral valve opening or
the onset of transmitral flow. IVRT was taken as the time in
milliseconds from the end of ejection to the onset of LV fill-
ing. All echocardiograms were interpreted by experienced
cardiologists who were blinded to the BNP levels.
Echocardiographic classifications
Normal ventricular function. Normal ventricular function
was defined by normal LV end-diastolic (3.5-5.7) and end-
systolic dimensions (2.5-3.6), no major wall motion abnormali-
ties, an ejection fraction of >50%, and no evidence of
impaired or restrictive relaxation abnormalities.
Systolic dysfunction. Systolic dysfunction was defined by
an ejection fraction less than 50% or either global hypokinesis
or discrete wall motion abnormalities.
Diastolic dysfunction. Diastolic dysfunction was defined as
impaired relaxation, restrictive pattern, and pseudonormal
pattern on the basis of the definitions below.
1. Impaired relaxation: E/A ratio <1 and deceleration time
>240 ms in patients <55 years old and E/A ratio <0.8 plus
deceleration time >240 ms in patients 55 years old.
IVRT measurements, which were available in approxi-
mately one half of the patients, was >90 ms in 90% or
more of patients were abnormal E/A ratio changes or
deceleration time >240 ms.
2. Restrictive: E/A ratio >1.5 and deceleration time <150 ms.
Confirming evidence included pulmonary vein diastolic >
pulmonary vein systolic, pulmonary A reversal > for-
ward mitral A wave duration, pulmonary vein diastolic
flow reversal, IVRT < 70 ms. Confirming evidence by one
or more of the above was seen in >50% of patients.
3. Pseudonormal E/A ratio >1 and deceleration time >240
ms. Confirmation by Valsalva maneuver when possible.
Systolic plus diastolic-restrictive. Systolic plus diastolic-
restrictive was defined as ejection fraction less than 50% with
global hypokinesis or discrete wall motion abnormalities and
deceleration time <150 ms.
Measurement of BNP plasma levels
During initial evaluations, a small sample (5 mL) was col-
lected into tubes containing potassium EDTA (1 mg/mL
blood). BNP was measured with the Triage B-Type Natriuretic
Peptide test (Biosite Diagnostics, San Diego, Calif). The Triage
BNP Test is a fluorescence immunoassay for the quantitative
determination of BNP in whole blood and plasma specimens.
The concentration of BNP in the specimen is proportional to
the fluorescence bound in the detection lane of the device
and was quantified by the portable Triage meter. When possi-
ble, BNP levels were measured in whole blood and processed
within 4 hours. Otherwise, samples were spun down and the
plasma frozen until the sample was analyzed (1-2 days). Figure
1 shows a high correlation between the assay used in this
study (Biosite Diagnostics) and the Shiono radioimmunoassay
(RIA) (Shionogi, Osaka, Japan). The range of detectable levels
are 1 to 1300 pg/mL. The average 95% confidence limit of the
analytical sensitivity of the test is less than 5 pg/mL (95% con-
fidence interval 0.2-4.8 pg/mL). The average total imprecision
is 10.1% at mean values of 28 pg/mL and 16.2% at mean levels
of 1080.4 pg/mL. There is no significant cross-reactivity with
endothelin-1, -atrial natriuretic peptide, or aldosterone.
Statistical analysis
Group comparisons of BNP values were made with t tests for
independent samples and analyses of variance. In all cases these
were computed with raw BNP values and repeated with log-
transformed BNP values because the BNP distribution was posi-
tively skewed. Both versions yielded the same conclusions.
Sensitivity, specificity, and accuracy were computed for
BNP with a selection of possible cut points. The diagnostic
utility of BNP alone was compared with the echocardio-
graphic probability of LV dysfunction with receiver-operator
characteristic (ROC) curves.
American Heart Journal
March 2001 Maisel et al 368
Results
The characteristics of the 200 patients are shown in
Table I. Fifty-two percent of patients had unsubstanti-
ated complaints of dyspnea, whereas the remaining
were essentially asymptomatic. Nearly all patients had
risk factors for heart disease, including 46% with a his-
tory of coronary artery disease.
Figure 2 presents BNP values (mean and SE) for
patients classified as either normal LV function or
abnormal LV function groups. Patients diagnosed
with abnormal LV function (n = 95) had a mean BNP
concentration of 489 75 pg/mL, whereas the normal
LV function group (n = 105) had a mean BNP concen-
tration of 29.5 62.4 pg/mL. The group difference
was significant in raw (P < .001) and log (P < .001)
form.
Figure 3 shows the breakdown of patients with
abnormal LV function into purely systolic (n = 53),
purely diastolic (n = 42), and the combination of sys-
tolic plus diastolic (n = 14) on the basis of echocardiog-
raphy. Values for all abnormal LV function groups are
significantly higher than for the normal LV function
group (P < .001). Patients with systolic plus diastolic-
restrictive dysfunction had significantly higher BNP val-
ues (1077 272 pg/mL) than pure systolic (567 113
pg/mL) or pure diastolic function alone (391 89
pg/mL) (P < .0001). The ejection fraction of the sys-
tolic plus diastolic-restrictive group was 34% versus
45% for the pure systolic patients.
American Heart Journal
Volume 141, Number 3 Maisel et al 369
Figure 1
Correlation between two assays for BNP: Triage Cardiac assay
(Biosite Diagnostics, and Shiono RIA, Shionogi), n = 42
patients. Measurements done in parallel, same day.
Figure 2
Mean and SEM for normal and abnormal LV dysfunction.
Figure 3
BNP values for the different subclasses of LV dysfunction,
namely, all systolic, all diastolic, and all systolic plus diastolic
dysfunction. The group systolic plus diastolic dysfunction is a
subgroup of all systolic dysfunction. Data are expressed as
mean SEM.
No. 200
Age (y) 65.32 0.9
Sex (male/female) 189/11
All normal 53%
All abnormal 48%
History of hypertension 65%
History of diabetes 34%
History of coronary artery disease 46%
History of shortness of breath 52%
History of edema 28%
Characteristics of all 200 patients recruited into the study. History included presence
or absence of diabetes, hypertension, or coronary artery disease and symptoms
included presence or absence of shortness of breath or edema when referred for
echocardiogram.
Table I. Patient characteristics
An ROC curve showing the sensitivity and specificity
of BNP against the echocardiography diagnosis for LV
function in all 200 patients is shown in Figure 4. The
area under the curve (accuracy) was 0.959 (0.932-
0.987).
Table II represents the sensitivity, specificity, posi-
tive and negative predictive values, and accuracy of
various BNP levels in determining LV function with use
of echocardiography as the gold standard. The differ-
ent cut points were picked from the ROC curve. As
can be seen, a BNP level cutoff value at 38.5 pg/mL
was 95% sensitive for the detection of LV dysfunction
and 66% specific. Levels at or below 38.5 pg/mL had a
negative predictive value of 93%. A BNP cut point of
75 pg/mL exhibited the best specificity (98%), best
positive predictive value (98%), and the highest accu-
racy (93%).
Table III shows characteristics of patients belonging
to the two groups (normal and abnormal LV function).
As can be seen, histories of hypertension, diabetes, and
coronary disease are frequently seen in both groups of
patients. Yet BNP levels >100 pg/mL were seen in only
1% of patients with normal ventricular function com-
pared with 80% of patients with abnormal ventricular
function (P < .001).
Figure 5 shows a depiction of all cardiac referrals for
assessment of LV function. Twenty-four percent of
patients in the referral group had known LV dysfunc-
tion. The mean BNP in this group was 798 106
pg/mL. Sixty percent of patients referred had unknown
LV function. Breakdowns of BNP levels in these groups
are discussed above.
Discussion
Early detection of LV dysfunction enables administra-
tion of treatment that can improve survival and increase
well-being.
2,6
But ventricular dysfunction may be diffi-
cult to diagnose because patients may be asymptomatic,
and abnormal findings on physical examination are
often absent.
3,4
Echocardiography, the most commonly
used method to diagnose LV dysfunction, is one of the
fastest growing procedures in cardiology.
25
However,
American Heart Journal
March 2001 Maisel et al 370
Figure 4
ROC curve comparing the sensitivity and specificity of BNP and
echocardiography diagnosis of LV dysfunction. Selected BNP
values are indicated in picograms per milliliter.
Positive Negative
BNP levels predictive predictive
(pg/mL) Sensitivity (%) Specificity (%) value (%) value (%) Accuracy (%)
38.5 95 (88-98) 66 (56-74) 71 (63-79) 93 (85-97) 80
46 93 (85-97) 80 (71-97) 81 (72-87) 81 (72-87) 86
55 92 (84-96) 86 (76-91) 85 (77-91) 92 (84-96) 89
65 88 (80-94) 91 (84-96) 90 (82-95) 90 (82-94) 90
75 86 (78-92) 98 (93-100) 98 (92-100) 89 (82-94) 93
Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of various BNP levels. The various cut points were obtained from ROC curve analysis.
Table II. BNP levels: normal versus abnormal
Normal Abnormal
LV function LV function
(n = 105) (n = 95)
Age >55 y 71% 90%
Clinical presentation
History of hypertension 56% 75%
History of diabetes 28% 40%
History of coronary artery disease 33% 60%
History of shortness of breath 42% 63%
History of edema 24% 32%
BNP levels (pg/mL)
>80 1% 85%
>100 1% 83%
>120 1% 80%
Clinical presentation and BNP levels among the two groups of patientsnormal and
abnormal LV function, by echocardiography. Abnormal group included either sys-
tolic dysfunction, diastolic dysfunction, or both systolic and diastolic dysfunction.
Table III. Normal LV function versus abnormal LV function
both the limited availability of echocardiography in
community settings and its expense may not make it
the best screening test for patients with low probability
of LV dysfunction.
Although studies using logistic regression models
with features of the history, physical examination,
chest x-ray film, and ECG have been used to predict the
probability of an abnormal echocardiogram,
7,26
a sim-
ple, rapid blood test that is both sensitive and specific
for LV dysfunction would be of significant clinical bene-
fit. The test should reliably rule out LV dysfunction
with an adequate positive predictive value.
The fact that increased levels of neurohumoral factors
such as norepinephrine, renin, and endothelin-1 have
been found to be significant prognostic predictors in
congestive heart failure (CHF) suggests an important
role of these vasoconstrictors in the pathogenesis of
CHF.
27-34
However, the use of these neurohumoral fac-
tors to diagnose LV dysfunction is impractical, in large
part because of difficult assay characteristics, general
instability of the compounds, and wide-ranging, often
overlapping values.
35,36
BNP is a 32 amino acid polypeptide containing a 17
amino acid ring structure common to all natriuretic
peptides.
37
The source of plasma BNP is cardiac ventri-
cles, which suggests that it may be a more specific indi-
cator of ventricular disorders than other natriuretic
peptides.
5,8,32
The nucleic acid sequence of the BNP
gene contains the destabilizing sequence tatttat,
which suggests that turnover of BNP messenger RNA is
high and that BNP is synthesized in bursts.
8
This release
appears to be directly proportional to ventricular vol-
ume expansion and pressure overload.
8-11,32
BNP is an
independent predictor of high LV pressure
10
and corre-
lates to NYHA classification.
11
BNP as a screen for LV dysfunction
BNP appears to be a useful addition in the evaluation
of possible CHF.
13-15,18
In a community-based study
where 1653 subjects underwent cardiac screening, the
negative predictive value of BNP of 18 pg/mL was 97%
for LV systolic dysfunction.
14
In a study of 122 consecu-
tive patients with suspected new heart failure referred
by general practitioners to a rapid-access heart failure
clinic for diagnostic confirmation, a BNP level of 76
pg/mL, chosen for its negative predictive value of 98%
for heart failure and similar to the cutoff value in the
current study, had a sensitivity of 97%, a specificity of
84%, and a positive predictive value of 70%.
13
Finally,
Davis et al
15
measured the natriuretic hormones atrial
natriuretic peptide and BNP in 52 patients with acute
dyspnea and found that admission plasma BNP concen-
trations more accurately reflected the final diagnosis
than did ejection fraction or concentration of plasma
atrial natriuretic peptide.
Point-of-care testing of BNP
This is the first study that examines the utility of a
rapid, point-of-care test for BNP to predict LV dysfunc-
tion as determined by echocardiography. This immuno-
American Heart Journal
Volume 141, Number 3 Maisel et al 371
Figure 5
A pie chart representing all referrals for echocardiography to evaluate LV function at San Diego Veterans Adminis-
tration Medical Center between June and October 1999. This group includes both outpatients and inpatients.
assay is automatic, uses 5 mL of whole blood, and is
small enough to use at the bedside or the echocardiog-
raphy clinic. Our findings suggest that BNP may be a
useful screen for patients with LV dysfunction and
yields an ROC curve of 0.959 compared to echocardiog-
raphy. This accuracy is similar to that of the prostate-
specific antigen for prostate cancer detection, which
had an area under the curve (AUC) of 0.94 and is supe-
rior to those of Papanicolaou smears and mammogra-
phy (AUC 0.70 and 0.85, respectively).
38-40
We found
that BNP levels were elevated in both systolic and dia-
stolic dysfunction, with the highest values being
reported in patients with systolic dysfunction plus a
decreased mitral valve deceleration time. Interestingly,
this group of patients has also been shown to have the
worst prognosis of all echocardiogram classifications of
LV dysfunction.
12,17
The European Society of Cardiology recently pub-
lished its recommendations regarding the diagnosis of
isolated diastolic heart failure, which included the pres-
ence of symptoms, presence of normal or mildly
reduced systolic function, and evidence of abnormal LV
relaxation and filling, diastolic distensibility, and dia-
stolic stiffness.
41
Our results are similar to those of Red-
field et al,
42
who studied 657 subjects with normal sys-
tolic function and found that BNP levels were higher in
those with isolated diastolic dysfunction. Although BNP
levels cannot differentiate between systolic and dia-
stolic dysfunction, elevated BNP levels likely represent
true diastolic dysfunction when systolic function is nor-
mal by echocardiography.
The results of this study can be extended to other
venues where rapid screening for left ventricular dys-
function is important.
12,17,18
We recently evaluated
point-of-care testing of 250 patients seen in the emer-
gency department for acute dyspnea. At the cut point
for BNP of 80 pg/mL, the negative predictive value
was 98%. BNP levels added significantly to variables
found in the history, physical examination, and the
laboratory. Patients whose dyspnea was subsequently
found to be the result of pulmonary disease had BNP
levels 10-fold less than those of patients with CHF.
Twenty-nine of 30 cases of acute dyspnea misdiag-
nosed by emergency department physicians would
have been correctly identified had BNP levels been
available.
43
Role of BNP in asymptomatic or minimally sympto-
matic LV dysfunction
It is estimated that 3% of the population above the
age of 45 years may have ventricular dysfunction and
that 50% of them may be asymptomatic.
44
The National
Institutes of Health sponsored Studies of Left Ventricu-
lar Dysfunction (SOLVD) in patients with asymptomatic
LV dysfunction, demonstrated humoral activation char-
acterized by increases in the natriuretic peptides with-
out activation of the circulating renin-angiotensin sys-
tem.
45
In the current study we found that nearly half
the patients were asymptomatic, yet BNP levels were
elevated in the majority of patients.
Our data amplify the suggestion of Mair et al,
46
who
concluded that there is sufficient evidence to encour-
age physicians to gain experience with BNP as a sup-
plement in the diagnosis of patients suspected of hav-
ing heart failure. The current study demonstrates the
usefulness of BNP for selecting patients for further car-
diac evaluation. It is clear that BNP should not replace
imaging techniques in the diagnosis of CHF because
these methods provide complementary information. An
increase in BNP is serious enough to warrant follow-up
echocardiography. Because BNP also provides informa-
tion on neurohormonal activation in CHF, which is
independent and of additive prognostic value to hemo-
dynamic variables, BNP might also be helpful for the
cardiologist to monitor therapy and disease course in
patients with CHF and for estimating prognosis in these
patients.
47,48
Limitations
This was an observational study done at a single Vet-
erans hospital, so one must be careful about generaliz-
ing the results to the entire population. Both the AUC
from an ROC, as well as the negative predictive values
are dependent on the patient population studied. Our
population represents generally older, predominantly
male, veterans.
Echocardiographic recordings form the basis of the
diagnosis of systolic and diastolic dysfunction in the
current study. Numerous previous reports have vali-
dated the ability of cardiac ultrasonography to detect
abnormalities of contractile function and to quantitate
LV volumes and ejection fraction.
23,24
All patients in
this study so designated had clear-cut evidence of LV
systolic dysfunction. Although diastolic dysfunction
implies an abnormal relationship between LV volume
and pressure, echocardiography is capable of assessing
only parameters related to volume. Therefore trans-
mural and pulmonary venous flow velocities provide
only indirect measurements of diastolic performance.
Nevertheless, these parameters have been shown to
provide reliable markers of impaired diastolic function
and are applied for this purpose in clinical practice.
Finally, in this study BNP is being used to identify
any impairment of ventricular function rather than
significant impairment. Thus symptoms in such
patients are not necessarily of cardiac origin and could
challenge the value of labeling those patients as abnor-
mal with BNP.
Conclusion
An easy, rapid test for BNP, which can be performed
at the bedside or clinic, with a whole blood sample,
American Heart Journal
March 2001 Maisel et al 372
can reliably predict the presence or absence of LV dys-
function on echocardiography. We believe that BNP may
be an excellent screening tool for LV dysfunction, espe-
cially in the community where the greatest burden of dis-
ease exists and where there is limited access to echocar-
diography. In this setting it is likely that BNP analysis
would greatly assist in appropriateness of patient referral
and in the optimization of drug therapy.
References
1. Sander GE, McKinnie JJ, Greenberg SS, et al. Angiotensin-converting
enzyme inhibitors and angiotensin II receptor antagonists in the treat-
ment of heart failure caused by left ventricular systolic dysfunction.
Prog Cardiovasc Dis 1999;41:265-300.
2. Pfeifer MA, Braunwald E, Moye LA, et al. Effect of captopril on mor-
tality and morbidity in patients with left ventricular dysfunction after
myocardial infarction: results of the Survival and Ventricular
Enlargement trial: the SAVE Investigators. N Engl J Med 1992;
327:669-77.
3. Stevenson LW. The limited availability of physical signs for estimating
hemodynamics in chronic heart failure. JAMA. 1989;261:884-8.
4. Remes J, Miettinen H, Reunanen A, et al. Validity of clinical diagnosis
of heart failure in primary health care. Eur Heart J 1991;12:315-21.
5. Struthers AD. Prospects for using a blood sample in the diagnosis of
heart failure. Q J Med 1995;88:303-6.
6. Deveraux RB, Liebson PR, Horan MJ. Recommendations concerning
use of echocardiography in hypertension and general population
research. Hypertension 1987;9:97-104.
7. Talreja D, Gruver C, Sklenar J, et al. Efficient utilization of echocar-
diography for the assessment of left ventricular systolic function. Am
Heart J 2000;139:393-8.
8. Nagagawa O, Ogawa Y, Itoh H, et al. Rapid transcriptional activa-
tion and early mRNA turnover of BNP in cardiocyte hypertrophy:
evidence for BNP as an emergency cardiac hormone against ven-
tricular overload. J Clin Invest 1995;96:1280-7.
9. Yoshimura M, Yasue H, Okamura K, et al. Different secretion pat-
tern of atrial natriuretic peptide and brain natriuretic peptide in
patients with CHF. Circulation 1993;87:464-9.
10. Maeda K, Tsutamato T, Wada A, et al. Plasma brain natriuretic pep-
tide as a biochemical marker of high left ventricular end-diastolic
pressure in patients with symptomatic left ventricular dysfunction. Am
Heart J 1998;135:825-32.
11. Clerico A, Iervasi G, Chicca M, et al. Circulating levels of cardiac
natriuretic peptides (ANP and BNP) measured by highly sensitive
and specific immunoradiometric assays in normal subjects and in
patients with different degrees of heart failure. J Endocrine Invest
1998;21:170-9.
12. Wallen T, Landahl S, Hedner T, et al. Brain natriuretic peptide pre-
dicts mortality in the elderly. Heart 1997;77:264-7.
13. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic pep-
tides in assessment of patients with possible new heart failure in pri-
mary care. Lancet 1997;350:1347-51.
14. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection
of left-ventricular systolic dysfunction. Lancet 1998;351:13-7.
15. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic pep-
tide in assessment of acute dyspnea. Lancet 1994;343:440-4.
16. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensa-
tion of endogenous cardiac natriuretic peptide system in chronic
heart failure: prognostic role of plasma brain natriuretic peptide
concentration in patients with chronic symptomatic left ventricular
dysfunction. Circulation 997;96:509-16.
17. Yamamoto K, Burnett JC Jr, Jougasaki M, et al. Superiority of brain
natriuretic peptide is related to diastolic dysfunction in hypertension.
Clin Exp Pharmcol Physiol 1997;24:966-8.
18. Koon J, Hope J, Garcia A, et al. A rapid bedside test for brain natri-
uretic peptide accurately predicts cardiac function in patients referred
for echocardiography [abstract]. J Am Coll Cardiol 2000;35:419A.
19. Yu CM, Sanderson JE, Shum IOL, et al. Diastolic dysfunction and
natriuretic peptides in systolic heart failure. Eur Heart J 1996;17:
1694-702.
20. Murdoch DR, Byrne J, Morten JJ. Brain natriuretic peptide is stable
in whole blood and can be measured using a simple rapid assay:
implications for clinical practice. Heart 1997;78:594-7.
21. Klinge R, Hystad M, Kjekshus J, et al. An experimental study of car-
diac natriuretic peptides as markers of development of CHF. Scand
J Clin Lab Invest 1998;58:683-9.
22. Edvinsson L, Ekman R, Hedner P, et al. CHF: involvement of perivas-
cular peptides reflecting activity in sympathetic, parasympathetic
and afferent fibers. Eur J Clin Invest 1990;20:85-9.
23. Feigenbaum H. Echocardiography. 6th ed. Philadelphia: Lea &
Febiger; 1999.
24. Schiller NB, Acquatella H, Ports TA, et al. Left ventricular volume
from paired biplane two-dimensional echocardiography. Circula-
tion 1979;60:547-55.
25. Drumholz HM, Douglas PS, Goldman L, et al. Clinical utility of
transthoracic two-dimensional and Doppler echocardiography. J
Am Coll Cardiol 1994;24:125-31.
26. Gillespie ND, McNeill G, Pringle T, et al. Cross-sectional study of
contribution of clinical assessment and simple cardiac investigations
to diagnosis of left ventricular systolic dysfunction in patients admit-
ted with acute dyspnea. BMJ 1997;314:936-40.
27. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a
guide to prognosis in patients with chronic congestive heart failure.
N Engl J Med 1984;311:819-23.
28. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroen-
docrine activation in patients with left ventricular dysfunction with
and without congestive heart failure: a substudy of the Studies of Left
Ventricular Dysfunction (SOLVD). Circulation 1990;82;1724-9.
29. Rouleau JL, de Champlain J, Klein M, et al. Activation of neurohu-
moral systems in post infarction left ventricular dysfunction. J Am
Coll Cardiol. 1993;22:390-8.
30. Remes J, Tikkanen, I, Fyhrquist F, et al. Neuroendocrine activity in
untreated heart failure. Br Heart J 1991;65:249-55.
31. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating car-
diovascular functioning patients with severe congestive heart failure
and their relation to mortality. Circulation. 1990;82:1730-6.
32. Tsutamoto T, Hisanaga T, Fukai D, et al. Prognostic value of plasma
intercellular adhesion molecule-1 and endothelin-1 concentration in
patients with chronic congestive heart failure. Am J Cardiol 1995;
76:803-8.
33. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril
with hydralazine-isosorbide dinitrate in the treatment of chronic con-
gestive heart failure. N Engl J Med 1991;325:303-10.
34. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces
dose-related improvements in left ventricular function and survival in
subjects with chronic heart failure. Circulation 1996;94:2807-16.
35. Klinge R, Hystad M, Kjekshus J, et al. An experimental study of car-
diac natriuretic peptides as markers of development of CHF. Scand
J Clin Lab Invest 1998;58:683-9.
36. Edvinsson L, Ekman R, Hedner P, et al. CHF: involvement of perivas-
American Heart Journal
Volume 141, Number 3 Maisel et al 373
cular peptides reflecting activity in sympathetic, parasympathetic
and afferent fibers. Eur J Clin Invest 1990;20:85-9.
37. Cheung BMY, Kumana CR. Natriuretic peptides-relevance in car-
diac disease. JAMA 1998;280:19839-40.
38. Jacobsen SJ, Bergstral EJ, Guess HA, et al. Predictive properties of
serum prostate-specific antigen testing in a community-based setting.
Arch Intern Med 1996;156:2462-8.
39. Swets JA, Getty DJ, Pickett RM, et al. Enhancing and evaluating
diagnostic accuracy. Med Decis Making 1991;11:9-18.
40. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy.
Am J Epidemiol 1995;141:680-9.
41. Anonymous. How to diagnose diastolic heart failure. Eur Heart J
1998;19:990-1003.
42. Redfield MR, Mahoney DW, Jacobsen SJ, et al. Isolated diastolic
dysfunction in the community. Circulation 1999;381(1 Suppl).
I381
43. Dao Q, Krishnawamy P, Kasanegra R, et al. Usefulness of a rapid,
bedside test for brain natriuretic peptide in the evaluation of patients
presenting to the emergency room with possible congestive heart
failure [abstract]. J Am Coll Cardiol In press.
44. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and
asymptomatic left-ventricular systolic dysfunction in an urban popu-
lation. Lancet 1997;350:829-33.
45. SOLVD Investigators. Effect of enalapril on mortality and the devel-
opment of heart failure in asymptomatic patients with reduced left
ventricular ejection fractions and congestive heart failure. N Engl J
Med 1991;325:293-302.
46. Mair J, Friedl W, Thomas S, et al. Natriuretic peptides in assessment
of left-ventricular dysfunction. J Clin Lab Invest 1999;59(230
Suppl):132-42.
47. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart
failure guided by plasma amino terminal brain natriuretic peptide
(N-BNP) concentrations. Lancet 1994;355:1126-30.
48. Murdoch DR, McDonaugh TA, Byrne J, et al. Titration of vasodilator
therapy in chronic heart failure according to plasma brain natri-
uretic peptide concentration: randomized comparison of hemody-
namic and neuroendocrine effects of tailored versus empirical ther-
apy. Am Heart J 1998;138:1126-32.
American Heart Journal
March 2001 Maisel et al 374
Receive tables of contents by E-mail
To receive the tables of contents by e-mail, sign up through our web site at
http://www. mosby.com/ahj
Choose E-mail notification
Simply type your e-mail address in the box and click on the subscribe button
Alternatively, you may send an e-mail message to
majordomo@mosby.com
Leave the subject line blank, and type the following as the body of your message:
subscribe ahj_toc
You will receive an e-mail to confirm that you have been added to the mailing list.
Note that TOC e-mails will be sent out when a new issue is posted to the Web site.